Navigation Links
MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology
Date:10/15/2009

GAITHERSBURG, Md., Oct. 15 /PRNewswire/ -- MedImmune today announced that researchers will present data on several inflammatory disease programs at the annual meeting of the American College of Rheumatology, from October 17 to 21, 2009 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

"Through our research into novel disease pathways involved in autoimmune disorders, we continue to fulfill our mission of using scientific excellence to deliver life-changing medicines for patients with rheumatic diseases," said Anthony Coyle, PhD., vice president, head of respiratory, inflammation, and autoimmune disease research. "Representing some of our most recent progress, we are pleased to share data relevant to the development of new therapies for conditions such as lupus, rheumatoid arthritis, and scleroderma."

The schedule for MedImmune's nine posters and two oral presentations at the meeting, starting on Saturday October 17, is as follows:

  • Relationship Between Disease Activity and Type 1 Interferon- and Other Cytokine-Inducible Gene Expression in Blood in Dermatomyositis and Polymyositis (Oral Presentation)-Steven Greeberg, Ph.D., Sunday, October 18 at 3:00 p.m. in Room 202 B
  • In Vitro and In Vivo Properties of MEDI-571, a Human Anti IL-17A Antibody in Development for the Treatment of Patients with Rheumatoid Arthritis - Matthew Sleeman, Ph.D., Sunday, October 18 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 8
  • Utilising Assay Systems Relevant to IL-6 Mechanisms in Rheumatoid Arthritis to Demonstrate Efficacy of a Novel Human Anti-IL-6 Antibody, CAT6001 -Donna Finch, Ph.D., Sunday, October 18 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 45, Abstract: 587
  • MEDI5117: A Human High Affinity Anti-IL-6 Monoclonal Antibody with Enhanced Serum Half-Life in Development for the Treatment of Inflammation and Rheumatological Diseases - Jacques Moisan, Ph.D., Sunday, October 18 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 401
  • Tissue Plasminogen Activator (tPA) Restores Normal Fibrinolysis / Coagulation Balance in Kidney and Reverses Clinical Score in Skin in a Murine Graft-Versus-Host Disease Model of Scleroderma: Proof of Concept for Therapeutic Fibrinolysis in Scleroderma - Timothy Burwell, B.Sc., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1062
  • Neutralization of Angiopoietin 2 Reduces Disease in Murine Arthritis and Augments Efficacy of Anti-TNF Treatment - Brian Naiman, MS., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 666
  • Critical Requirement of RAGE for Development of Lung Fibrosis in An Experimental Model of Systemic Sclerosis -Tracy Delaney, M.Sc., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1053
  • Depletion of Inducible Co-Stimulator (ICOS) Bearing T Cells Inhibits Expansion of T Follicular Helper Cells (TFH) and Prevents Disease in a Graft Versus Host Mouse Model of Scleroderma - Gianluca Carlesso, Ph.D., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1065
  • Autoimmune-Driven Skin Fibrosis: The Critical Requirement for IFNAR1 in An Experimental Model of Systemic Sclerosis - Tracy Delaney, M.Sc., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1067
  • Human S100 Proteins Differentially Regulate Pro-Inflammatory Cytokine Release and Cell Migration - Bo Chen, Ph.D., Tuesday, October 20 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1331
  • CAM-3001; a Novel Human Monoclonal Antibody against GM-CSFR-a, in Subjects with Rheumatoid Arthritis (RA): Results of a Phi Study (Oral Presentation) - Gerd-R Burmester, M.D., Monday, October 19 from 9:00 a.m. - 11:00 a.m. in Hall D, Abstract: 1926

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.

SOURCE MedImmune


'/>"/>
SOURCE MedImmune
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors
2. HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A (H1N1)
3. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
4. MedImmune Announces Zook as President
5. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
6. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
7. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
8. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
9. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
10. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
11. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... , Dec. 3, 2016  In five studies ... Hematology (ASH) Annual Meeting and Exposition in ... engineering methods to improve the delivery of life-saving treatments ... new methods are designed to carry therapies directly to ... most, which could provide a substantial advantage over traditional, ...
(Date:12/2/2016)... , Dec. 2, 2016 Amgen (NASDAQ: ... today announced the submission of a Marketing Authorization Application (MAA) ... biosimilar candidate to Avastin ® (bevacizumab). The companies believe ... the EMA. "The submission of ABP 215 ... to expand our oncology portfolio," said Sean E. Harper ...
(Date:12/2/2016)... ... ... Aerocom Healthcare ( http://www.aerocomhealthcare.com ), representing the global leader ... for tracking and securing medications at booth 676 at the ASHP Midyear Clinical ... a proven solution for tracking medications via its system from pharmacy to nursing ...
(Date:12/2/2016)... ... December 02, 2016 , ... The ... to collaboratively developing improved chemistry, manufacturing and control technologies for the pharmaceutical ... with robust, probe-based sampling. , Online liquid chromatography analysis is becoming ...
Breaking Biology Technology:
(Date:11/19/2016)... -- Securus Technologies, a leading provider of civil and ... and monitoring, announced today that it has offered a ... independent technology judge determine who has the largest and ... calling platform, and the best customer service. ... what we do – which clearly is not the ...
(Date:11/17/2016)... it has just released a new white paper authored by Zettar that covers the ... transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be a complicated endeavor ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
Breaking Biology News(10 mins):